Ocrelizumab biosimilar (Amgen)

奥瑞珠单抗生物类似药 (安进)

Report date: 2026/03/31 20:00:21

Base Information

Drug NameOcrelizumab biosimilar (Amgen)

Drug Alias NameABP 692ABP-692

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsMultiple Sclerosis, Relapsing-Remitting

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumBulgaria +[21]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc

Inactive CompaniesN/A

Active IndicationsMultiple Sclerosis, Relapsing-Remitting

Inactive IndicationsN/A

Other Information

ATC CodeN/A